TL;DR
This study reveals that Centromere protein U (CENPU) is a key driver in gastric cancer, promoting cell growth and glycolysis by upregulating High Mobility Group Box 2 (HMGB2). Targeting CENPU could be a promising therapeutic strategy for this deadly disease.
What Problem Does This Paper Address?
Gastric cancer remains a leading cause of cancer-related deaths worldwide, despite advances in diagnosis and treatment. A significant challenge is understanding the molecular mechanisms that drive its aggressive progression. Cancer cells exhibit a metabolic shift, particularly enhanced glycolysis (the "Warburg effect"), to fuel their rapid proliferation and invasiveness. While both CENPU and HMGB2 have been implicated in various cancers, their specific interplay and role in gastric cancer's metabolic reprogramming and proliferation remained unclear. This paper aims to elucidate the relationship between CENPU and HMGB2 in gastric cancer and their collective impact on cell growth and energy metabolism.
Methods
The researchers employed a multi-pronged approach to investigate CENPU's role in gastric cancer:
- Gene Expression Analysis: They utilized GEPIA (Gene Expression Profiling Interactive Analysis) to assess CENPU's expression in gastric cancer versus normal tissues.
- Quantitative PCR (qPCR) and Western Blotting: These techniques were used to measure CENPU mRNA and protein levels in gastric cancer cell lines (AGS, MKN45, HGC-27) compared to a normal gastric epithelial cell line (GES-1).
- Cell Proliferation Assays:
- MTT Assay: To assess overall cell viability and proliferation after manipulating CENPU levels.
- Colony Formation Assay: To evaluate the ability of cells to form colonies, a measure of sustained proliferation and survival.
- Glycolysis Measurement: Standard assay kits were used to quantify glucose consumption, lactate production, and total ATP content, key indicators of glycolytic activity.
- Gene Silencing and Overexpression: siRNA was used to knock down CENPU expression, while plasmids were used to overexpress CENPU and HMGB2. This allowed for the investigation of CENPU's functional impact and its relationship with HMGB2.
- Immunohistochemistry (IHC): Used on tumor tissues from a xenograft mouse model to visualize the expression of CENPU, HMGB2, and the proliferation marker Ki-67.
- Xenograft Tumor Model: Human gastric cancer cells were implanted into mice to study the in vivo effects of CENPU knockdown on tumor growth.
Datasets
The study utilized publicly available data from GEPIA for initial expression analysis. The primary experimental data was generated using human gastric cancer cell lines (AGS, MKN45, HGC-27) and a normal gastric epithelial cell line (GES-1). In vivo experiments were conducted using a xenograft mouse model.
Key Insights and Ideas
- CENPU as a Gastric Cancer Driver: The study firmly establishes CENPU as an upregulated protein in gastric cancer, suggesting its active role in the disease's development.
- CENPU Orchestrates Metabolic Reprogramming: The findings highlight that CENPU doesn't just affect cell division but also significantly influences how cancer cells generate energy, pushing them towards a more glycolytic metabolism.
- HMGB2 as a Crucial Downstream Mediator: The research uncovers a critical dependency: CENPU's pro-cancer effects are mediated through HMGB2. This suggests a hierarchical regulatory pathway where CENPU acts upstream of HMGB2.
- Therapeutic Potential of Targeting CENPU: By demonstrating that inhibiting CENPU has significant anti-cancer effects, the study positions CENPU as a potential therapeutic target, offering a new avenue for combating gastric cancer.
Key Results
- CENPU Upregulation: CENPU mRNA and protein levels were significantly higher in gastric cancer cell lines (AGS, MKN45, HGC-27) compared to the normal GES-1 cell line.
- Inhibition of Proliferation: Knockdown of CENPU significantly suppressed cell proliferation, as evidenced by reduced MTT assay values and fewer colonies formed in colony formation assays. Conversely, CENPU overexpression enhanced these processes.
- Suppression of Glycolysis: CENPU knockdown led to decreased glucose consumption, lactate production, and ATP generation. This effect was reversed by CENPU overexpression. The expression of key glycolytic enzymes (LDHA, GLUT1, HK2) was also reduced upon CENPU knockdown.
- HMGB2 Dependency: CENPU and HMGB2 expression showed a positive correlation. Knockdown of CENPU reduced HMGB2 levels, while CENPU overexpression increased them. Crucially, the anti-cancer effects of CENPU knockdown on proliferation and glycolysis could be rescued by overexpressing HMGB2, confirming CENPU's HMGB2-dependent mechanism.
- In Vivo Tumor Suppression: In a xenograft mouse model, CENPU knockdown significantly reduced tumor volume and weight, further supporting its role in promoting tumor growth. IHC analysis confirmed reduced CENPU, HMGB2, and Ki-67 expression in tumors from CENPU-knockdown mice.
Limitations and Future Work
The authors acknowledge that while CENPU's role in gastric cancer is demonstrated, the precise molecular mechanisms by which CENPU regulates HMGB2 expression require further investigation. Future work could focus on identifying the specific signaling pathways involved in this interaction. Additionally, exploring the therapeutic efficacy of CENPU inhibitors in preclinical models and eventually in clinical trials would be a logical next step. The study also primarily used cell lines and a xenograft model; further validation in patient-derived organoids or primary tumor samples could strengthen the findings.
Summary updated